Cargando…

Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial

Patients with rare solid tumors treated on early phase trials experience toxicities from their tumors and treatments. However, limited data exist to describe the detailed symptom burden suffered by these patients, particularly those with rare solid tumors treated with immunotherapy. We performed a p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mendoza, Tito R., Hong, David S., Peterson, Christine B., Stephen, Bettzy, Dumbrava, Ecaterina, Pant, Shubbam, Tsimberidou, Apostolia Maria, Yap, Timothy Anthony, Sheshadri, Ajay, Altan, Mehmet, George, Goldy, Castillo, Lilibeth, Rodriguez, Enedelia, Gong, Jing, Subbiah, Vivek, Janku, Filip, Fu, Siqing, Piha-Paul, Sarina A., Ahnert, Jordi Rodon, Karp, Daniel D., Cleeland, Charles, Meric-Bernstam, Funda, Naing, Aung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399082/ https://www.ncbi.nlm.nih.gov/pubmed/35999229 http://dx.doi.org/10.1038/s41598-022-16588-3

Ejemplares similares

Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory
por: Mendoza, Tito, et al.
Publicado: (2020)

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
por: Yao, Shuyang, et al.
Publicado: (2022)

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
por: Subbiah, Vivek, et al.
Publicado: (2020)

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic
por: Dembla, Vikas, et al.
Publicado: (2018)

Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials
por: Sen, Shiraj, et al.
Publicado: (2018)

Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer
por: Wang, Zhijie, et al.
Publicado: (2017)

Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study
por: Thein, Kyaw Z., et al.
Publicado: (2022)

Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer
por: Wang, Yudong, et al.
Publicado: (2018)

Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer
por: Son, Ji, et al.
Publicado: (2023)

Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience
por: Fu, Siqing, et al.
Publicado: (2015)

Phase 1 trial of ADI‐PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors
por: Yao, Shuyang, et al.
Publicado: (2021)

A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies
por: Piha-Paul, Sarina A, et al.
Publicado: (2021)

Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
por: Reilley, Matthew J., et al.
Publicado: (2017)

Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study
por: George, Goldy C, et al.
Publicado: (2019)

Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience
por: Hou, Ming-Mo, et al.
Publicado: (2016)

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience
por: Wang, Zhijie, et al.
Publicado: (2016)

Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors
por: Jardim, Denis L., et al.
Publicado: (2014)

Phase 2 study of pembrolizumab in patients with advanced rare cancers
por: Naing, Aung, et al.
Publicado: (2020)

Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population
por: Wheler, Jennifer, et al.
Publicado: (2013)

Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience
por: Goldstein, Jennifer B., et al.
Publicado: (2017)

Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
por: Habra, Mouhammed Amir, et al.
Publicado: (2019)

Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation
por: Chelariu-Raicu, Anca, et al.
Publicado: (2023)

Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies
por: Subbiah, Vivek, et al.
Publicado: (2016)

Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas
por: Jimenez, Camilo, et al.
Publicado: (2020)

Personalized cancer therapy—leveraging a knowledge base for clinical decision-making
por: Dumbrava, Ecaterina Ileana, et al.
Publicado: (2018)

Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology
por: Vo, Henry Hiep, et al.
Publicado: (2022)

Associations between the gut microbiome and fatigue in cancer patients
por: Hajjar, Joud, et al.
Publicado: (2021)

Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi‐arm phase Ib study
por: Thein, Kyaw Zin, et al.
Publicado: (2021)

Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
por: Thein, Kyaw Zin, et al.
Publicado: (2021)

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
por: Groisberg, Roman, et al.
Publicado: (2017)

Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications
por: Dumbrava, Ecaterina E. Ileana, et al.
Publicado: (2019)

Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials
por: How, Jeffrey A., et al.
Publicado: (2022)

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
por: Park, Haeseong, et al.
Publicado: (2016)

Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies
por: Wang, Yudong, et al.
Publicado: (2020)

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers
por: Sen, Shiraj, et al.
Publicado: (2018)

Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials
por: Subbiah, Ishwaria M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_03aord6pmkse7nn9cgq5tdff5l